BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

GlycoMimetics, Inc. Announces Progress from Its Novel Compounds as Presented at 2012 American Society of Hematology Annual Meeting


12/11/2012 10:23:33 AM

GAITHERSBURG, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (GMI), a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that the company and its collaborators delivered an oral presentation and two posters at the 2012 American Society of Hematology (ASH) Annual Meeting and Exposition. The oral presentation, which was given on December 9 at the meeting’s venue at the Georgia World Congress Center in Atlanta, highlighted data from GMI’s lead program GMI-1070, which is now partnered with Pfizer. The posters highlighted data from GMI’s E-selectin antagonist program, which the company is developing to treat acute myeloid leukemia (AML) and other cancers.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->